HBIO · Harvard Bioscience Inc
United States · RS rating 96 · As of 2026-10-14
| Price | 8.15 USD |
|---|---|
| 1-day change | -1.4% |
| RS rating (overall / 1M / 3M / 12M) | 96 / 81 / 94 / 95 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 38 / 58 / 56 |
| Industry group (rank) | Medical-Products (98) |
| EPS growth Q/Q | -100.0% |
| Sales growth Q/Q | +15.3% |
| Distance from 52-week high | +4.8% |
| Market cap (USD) | $30.6M |